Verastem, Inc.

Verastem Oncology is a biopharmaceutical company dedicated to the development and commercialization of novel medicines for patients diagnosed with RAS/MAPK pathway-driven cancers. Headquartered in Needham, Massachusetts, the company's mission is to ensure that cancer patients have access to treatment options, fostering hope through innovative therapies.

The company's key product is AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets), an FDA-approved combination therapy for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. Verastem Oncology's pipeline is focused on small molecule drugs that inhibit critical signaling pathways in cancer, including RAF/MEK inhibition (avutometinib), FAK inhibition (defactinib), and KRAS G12D inhibition (VS-7375). These investigational therapies are being evaluated for various solid tumors, such as LGSOC, pancreatic cancer, non-small cell lung cancer, and colorectal cancer.

In April 2026, Verastem Oncology launched its "Reimagine Recurrent LGSOC" campaign to raise awareness and encourage earlier use of AVMAPKI® FAKZYNJA® CO-PACK. The company also presented two-year median follow-up data for this combination therapy at the SGO 2026 Annual Meeting. Having transitioned to a commercial-stage company in 2025, Verastem reported preliminary net product revenues of approximately $30.9 million for AVMAPKI® FAKZYNJA® CO-PACK for the full year 2025. Leadership changes in December 2025 saw Dan Paterson continue as President and CEO, with Michael Kauffman appointed President of Development and John Johnson as Chairman of the Board. The company continues to advance its clinical development program for VS-7375, a potential best-in-class oral KRAS G12D inhibitor.